The Cambridge genomics spinout has secured $5.4m in additional series A funding from drug maker Taiho Pharmaceutical.
Storm Therapeutics, a UK-based genomics research spinout from University of Cambridge, secured £4m ($5.4m) in a series A extension yesterday from Taiho Ventures, the corporate venturing arm of drug maker Taiho Pharmaceutical.
Storm received an initial $16m series A tranche in June 2016 that included $4m each from commercialisation firm Touchstone Innovations and Cambridge Innovation Capital, a patient capital fund affiliated with the university.
Merck Ventures and Pfizer Venture Investments, respective strategic investment divisions of pharmaceutical firms Merck and Pfizer, also made $4m contributions…
